Oral Targeted Therapies and Central Nervous System (CNS) Metastases

Michael P. Gabay; Scott M. Wirth; Joan M. Stachnik; Colleen L. Overley; Katie E. Long; Linda R. Bressler; John L. Villano

doi:10.1007/s40263-015-0283-6

Oral Targeted Therapies and Central Nervous System (CNS) Metastases

Michael P. Gabay, Scott M. Wirth, Joan M. Stachnik, Colleen L. Overley, Katie E. Long, Linda R. Bressler, John L. Villano

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare.

Original language	English
Article number	283
Pages (from-to)	935-952
Number of pages	18
Journal	CNS Drugs
Volume	29
Issue number	11
DOIs	https://doi.org/10.1007/s40263-015-0283-6
State	Published - Nov 2015

Bibliographical note

Publisher Copyright:
© 2015 Springer International Publishing Switzerland.

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40263-015-0283-6

Cite this

@article{70eb5d96a2764a8096682e02c1e86522,

title = "Oral Targeted Therapies and Central Nervous System (CNS) Metastases",

abstract = "The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare.",

author = "Gabay, {Michael P.} and Wirth, {Scott M.} and Stachnik, {Joan M.} and Overley, {Colleen L.} and Long, {Katie E.} and Bressler, {Linda R.} and Villano, {John L.}",

note = "Publisher Copyright: {\textcopyright} 2015 Springer International Publishing Switzerland.",

year = "2015",

month = nov,

doi = "10.1007/s40263-015-0283-6",

language = "English",

volume = "29",

pages = "935--952",

number = "11",

}

TY - JOUR

T1 - Oral Targeted Therapies and Central Nervous System (CNS) Metastases

AU - Gabay, Michael P.

AU - Wirth, Scott M.

AU - Stachnik, Joan M.

AU - Overley, Colleen L.

AU - Long, Katie E.

AU - Bressler, Linda R.

AU - Villano, John L.

PY - 2015/11

Y1 - 2015/11

N2 - The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare.

AB - The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare.

UR - http://www.scopus.com/inward/record.url?scp=84947944004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947944004&partnerID=8YFLogxK

U2 - 10.1007/s40263-015-0283-6

DO - 10.1007/s40263-015-0283-6

M3 - Review article

C2 - 26563196

AN - SCOPUS:84947944004

SN - 1172-7047

VL - 29

SP - 935

EP - 952

JO - CNS Drugs

JF - CNS Drugs

IS - 11

M1 - 283

ER -

Oral Targeted Therapies and Central Nervous System (CNS) Metastases

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this